Compare BridgeBio Pharma Inc (BBIO) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Energy Select Sector SPDR Fund — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Energy Select Sector SPDR Fund trades at $56.89. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BBIO | XLE | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $62.57 |
52-Week Low | $44.81 | $42.12 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
XLE trades at $56.75, up 3.03% with a bullish technical signal from moving averages and oscillators. The ETF benefits from strong sector performance, ranking among top Sector SPDRs with 21% YTD gains (ETF Trends, July 2, 2026). Recent oil price volatility and geopolitical tensions drive energy sector attention, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains positive due to robust earnings growth expectations in energy, though overbought RSI signals near-term caution. Risks include oil price sensitivity and competition from clean energy ETFs. Analyst sentiment leans bullish with sector fundamentals strengthening amid disciplined capital expenditure and demand drivers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
